We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00983372
First Posted: September 24, 2009
Last Update Posted: October 15, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Mutual Pharmaceutical Company, Inc.
Results First Submitted: August 13, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Basic Science
Condition: Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Interventions: Drug: Colchicine
Drug: Diltiazem ER

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Twenty-four (24) healthy, non-smoking , male and female volunteers, consisting of members of the community at large, were enrolled in the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
53 subjects were screened, 13 were screen failures, 14 had schedule conflicts, 1 transferred to a different study, and 1 was not needed

Reporting Groups
  Description
Colchicine Alone / With Diltiazem (at Steady-state) [All subjects received each of the study treatments.] Each subject received one 0.6 mg colchicine tablet on Day 1 at 7:15 a.m. after an overnight fast of at least 10 hours, followed by a washout period of 14 days. On Days 15 to 20, each subject received one 240 mg diltiazem ER capsule at 7:15 a.m. Then, on Day 21, each subject received both one 0.6 mg colchicine tablet and one 240 mg diltiazem ER capsule at 7:15 a.m. after an overnight fast of at least 10 hours.

Participant Flow for 4 periods

Period 1:   Colchicine Alone
    Colchicine Alone / With Diltiazem (at Steady-state)
STARTED   24 
COMPLETED   24 
NOT COMPLETED   0 

Period 2:   14 Day Washout Period
    Colchicine Alone / With Diltiazem (at Steady-state)
STARTED   24 
COMPLETED   23 [1] 
NOT COMPLETED   1 
Withdrawal by Subject                1 
[1] subject withdrew consent due to schedule conflict - during washout period or diltiazem alone

Period 3:   Diltiazem ER Alone
    Colchicine Alone / With Diltiazem (at Steady-state)
STARTED   23 
COMPLETED   20 [1] 
NOT COMPLETED   3 
missed diltiazem dose                2 
Adverse Event                1 
[1] two subjects dropped due to missed diltiazem ER dose; one subject dropped due to vomitting

Period 4:   Colchicine With Diltiazem ER
    Colchicine Alone / With Diltiazem (at Steady-state)
STARTED   20 
COMPLETED   20 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Colchicine Alone / With Diltiazem (at Steady-state) [All subjects received each of the study treatments.] Each subject received one 0.6 mg colchicine tablet on Day 1 at 7:15 a.m. after an overnight fast of at least 10 hours, followed by a washout period of 14 days. On Days 15 to 20, each subject received one 240 mg diltiazem ER capsule at 7:15 a.m. Then, on Day 21, each subject received both one 0.6 mg colchicine tablet and one 240 mg diltiazem ER capsule at 7:15 a.m. after an overnight fast of at least 10 hours.

Baseline Measures
   Colchicine Alone / With Diltiazem (at Steady-state) 
Overall Participants Analyzed 
[Units: Participants]
 24 
Age 
[Units: Participants]
 
<=18 years   1 
Between 18 and 65 years   23 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 28.0  (8.0) 
Gender 
[Units: Participants]
 
Female   9 
Male   15 
Race (NIH/OMB) 
[Units: Participants]
 
American Indian or Alaska Native   2 
Asian   0 
Native Hawaiian or Other Pacific Islander   1 
Black or African American   3 
White   18 
More than one race   0 
Unknown or Not Reported   0 
Ethnicity (NIH/OMB) 
[Units: Participants]
 
Hispanic or Latino   1 
Not Hispanic or Latino   23 
Unknown or Not Reported   0 
Region of Enrollment 
[Units: Participants]
 
United States   24 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximum Plasma Concentration (Cmax)   [ Time Frame: serial pharmacokinetic blood samples drawn immediately prior to dosing on Days 1 and 21, and then 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 hours after dose administration ]

2.  Primary:   Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]   [ Time Frame: serial pharmacokinetic blood samples drawn immediately prior to dosing on Days 1 and 21, and then 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 hours after dose administration ]

3.  Primary:   Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]   [ Time Frame: serial pharmacokinetic blood samples drawn immediately prior to dosing on Days 1 and 21, and then 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 hours after dose administration ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Medical Director
Organization: Mutual Pharmaceutical Company, Inc.
phone: 215-697-1743
e-mail: clinicaltrials@urlmutual.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Vice President, Branded Products and Medical Affairs, Mutual Pharmaceutical Company, Inc.
ClinicalTrials.gov Identifier: NCT00983372     History of Changes
Other Study ID Numbers: MPC-004-08-1015
First Submitted: August 13, 2009
First Posted: September 24, 2009
Results First Submitted: August 13, 2009
Results First Posted: September 24, 2009
Last Update Posted: October 15, 2009